How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics.
Although amino-bisphosphonates (N-BPs) induce apoptosis of myeloma cells in vitro, most in-vivo studies fail to demonstrate a corresponding antitumour effect. This discrepancy might reflect the development of resistance to the antitumour effects of N-BP in myeloma cells when they are exposed to N-BP for a prolonged time. To test this hypothesis, two N-BP-sensitive human myeloma cell lines were continuously exposed to increasing concentrations of the N-BP alendronate for 6 weeks. During this treatment period, 10 out of 10 sublines developed reduced apoptotic and antiproliferative responses to alendronate treatment. This de novo alendronate resistance was accompanied by resistance to another N-BP (zoledronate) but not to an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase or Fas ligand. Importantly, N-BP-resistant myeloma cells also remained sensitive to conventional myeloma chemotherapeutics (melphalan, doxorubicin and vincristine). Further analysis of the N-BP-resistant cells revealed an increased activity of the N-BP-specific target enzyme farnesyl pyrophosphate synthase, without upregulation of its gene transcription. Our results suggest that continuous exposure of myeloma cells to alendronate leads to the development of N-BP resistance. This is associated with an increased activity of farnesyl pyrophosphate synthase and does not evolve from defective apoptotic pathways. Importantly, the antitumour effects of conventional myeloma chemotherapeutics are preserved in the N-BP-resistant myeloma cells.
Salomo
Morten
M
Department of Haematology, University of Copenhagen, Denmark. salomo@rh.dk
Jurlander
Jesper
J
Nielsen
Lars Bo
LB
Gimsing
Peter
P
D019386:Alendronate / Q000627:therapeutic use*; D019883:Alkyl and Aryl Transferases / Q000378:metabolism; D017209:Apoptosis; D015153:Blotting, Western / Q000379:methods; D004164:Diphosphonates / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D051228:Geranyltranstransferase; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D016014:Linear Models; D009101:Multiple Myeloma / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D016133:Polymerase Chain Reaction / Q000379:methods; D017211:Treatment Failure; D014407:Tumor Cells, Cultured; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019883:Alkyl and Aryl Transferases; D051228:Geranyltranstransferase; D019386:Alendronate